Drug Trial Radar · NCT06342310
RE104 Safety and Efficacy Study in Postpartum Depression
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Jun 14, 2024
Primary completion
May 22, 2025
Study completion Jun 16, 2025
Sponsor
- Lead sponsor
- Reunion Neuroscience IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.
Conditions
- Postpartum Depression
Interventions
RE104 for InjectionDrug
Single, subcutaneous dose of RE104 for Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total scoreTime frame: Day 7
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Reunion Investigational Site
Birmingham, Alabama
Reunion Investigational Site
Tucson, Arizona
Reunion Investigational Site
Santa Monica, California
Reunion Investigational Site
Boulder, Colorado
Reunion Investigational Site
Denver, Colorado
Reunion Investigational Site
Lauderhill, Florida
Reunion Investigational Site
Tampa, Florida
Reunion Investigational Site
Atlanta, Georgia
Reunion Investigational Site
Atlanta, Georgia
Reunion Investigational Site
Decatur, Georgia
Reunion Investigational Site
Marietta, Georgia
Reunion Investigational Site
Savannah, Georgia
Reunion Investigational Site
Honolulu, Hawaii
Reunion Investigational Site
Kansas City, Kansas
Reunion Investigational Site
Shreveport, Louisiana
Reunion Investigational Site
Baltimore, Maryland
Reunion Investigational Site
Rockville, Maryland
Reunion Investigational Site
Springfield, Massachusetts
Reunion Investigational Site
Novi, Michigan
Reunion Investigational Site
Albuquerque, New Mexico
Reunion Investigational Site
Buffalo, New York
Reunion Investigational Site
New York, New York
Reunion Investigational Site
New York, New York
Reunion Investigational Site
Chapel Hill, North Carolina
Reunion Investigational Site
Monroe, North Carolina
Reunion Investigational Site
Cleveland, Ohio
Reunion Investigational Site
Columbus, Ohio
Reunion Investigational Site
West Chester, Pennsylvania
Reunion Investigational Site
Austin, Texas
Reunion Investigational Site
Austin, Texas
Reunion Investigational Site
Austin, Texas
Reunion Investigational Site
Plano, Texas
Reunion Investigational Site
San Antonio, Texas
Reunion Investigational Site
Draper, Utah
Reunion Investigational Site
Salt Lake City, Utah
Reunion Investigational Site
Charlottesville, Virginia
Reunion Investigational Site
Seattle, Washington
Reunion Investigational Site
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.